Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease
Press Release Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease Treatment Could Help Restore Brain Functions Lost in Many Neurodegenerative Disorders LOS ANGELES, Calif., (September 12, 2023) – Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today […]
Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Press Release Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Treatment Could Help Restore Brain Functions Lost in Many Neurodegenerative Disorders LOS ANGELES, Calif., July 10, 2023 (GLOBE NEWSWIRE) — Spinogenix, […]
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
Press Release Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis Treatment Could Help Restore Brain Functions Lost in Many Neurodegenerative Disorders LOS ANGELES, Calif., June 07, 2021 (GLOBE NEWSWIRE) — Spinogenix, Inc. a pharmaceutical company focused on the development of novel synaptogenic small molecule therapies for central nervous […]
Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)
Press Release Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS) Treatment Could Help Restore Brain Functions Lost in Many Neurodegenerative Disorders LOS ANGELES, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) — Spinogenix, Inc. a preclinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today […]
